Agmatine improves locomotor function and reduces tissue damage following spinal cord injury

Guang Yu Chen Guang Yu, Alexander Marcillo, C. A. Fairbanks, G. L. Wilcox, R. P. Yezierski

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Clinically effective drug treatments for spinal cord injury (SCI) remain unavailable. Agmatine, an NMDA receptor antagonist and inhibitor of nitric oxide synthase (NOS), is an endogenous neuromodulator found in the brain and spinal cord. Evidence is presented that agmatine significantly improves locomotor function and reduces tissue damage following traumatic SCI in rats. The results suggest the importance of future therapeutic strategies encompassing the use of single drugs with multiple targets for the treatment of acute SCI. The therapeutic targets of agmatine (NMDA receptor and NOS) have been shown to be critically linked to the pathophysiological sequelae of CNS injury and this, combined with the non-toxic profile, lends support to agmatine being considered as a potential candidate for future clinical applications. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
Pages (from-to)3203-3207
Number of pages5
JournalNeuroReport
Volume11
Issue number14
StatePublished - Oct 28 2000

Fingerprint

Agmatine
Spinal Cord Injuries
N-Methyl-D-Aspartate Receptors
Nitric Oxide Synthase
Pharmaceutical Preparations
Neurotransmitter Agents
Spinal Cord
Wounds and Injuries
Brain
Therapeutics

Keywords

  • Agmatine
  • Locomotor function
  • Neuroprotection
  • Nitric oxide
  • NMDA

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Chen Guang Yu, G. Y., Marcillo, A., Fairbanks, C. A., Wilcox, G. L., & Yezierski, R. P. (2000). Agmatine improves locomotor function and reduces tissue damage following spinal cord injury. NeuroReport, 11(14), 3203-3207.

Agmatine improves locomotor function and reduces tissue damage following spinal cord injury. / Chen Guang Yu, Guang Yu; Marcillo, Alexander; Fairbanks, C. A.; Wilcox, G. L.; Yezierski, R. P.

In: NeuroReport, Vol. 11, No. 14, 28.10.2000, p. 3203-3207.

Research output: Contribution to journalArticle

Chen Guang Yu, GY, Marcillo, A, Fairbanks, CA, Wilcox, GL & Yezierski, RP 2000, 'Agmatine improves locomotor function and reduces tissue damage following spinal cord injury', NeuroReport, vol. 11, no. 14, pp. 3203-3207.
Chen Guang Yu GY, Marcillo A, Fairbanks CA, Wilcox GL, Yezierski RP. Agmatine improves locomotor function and reduces tissue damage following spinal cord injury. NeuroReport. 2000 Oct 28;11(14):3203-3207.
Chen Guang Yu, Guang Yu ; Marcillo, Alexander ; Fairbanks, C. A. ; Wilcox, G. L. ; Yezierski, R. P. / Agmatine improves locomotor function and reduces tissue damage following spinal cord injury. In: NeuroReport. 2000 ; Vol. 11, No. 14. pp. 3203-3207.
@article{e5cfcd0375544c68b7925c34089cab58,
title = "Agmatine improves locomotor function and reduces tissue damage following spinal cord injury",
abstract = "Clinically effective drug treatments for spinal cord injury (SCI) remain unavailable. Agmatine, an NMDA receptor antagonist and inhibitor of nitric oxide synthase (NOS), is an endogenous neuromodulator found in the brain and spinal cord. Evidence is presented that agmatine significantly improves locomotor function and reduces tissue damage following traumatic SCI in rats. The results suggest the importance of future therapeutic strategies encompassing the use of single drugs with multiple targets for the treatment of acute SCI. The therapeutic targets of agmatine (NMDA receptor and NOS) have been shown to be critically linked to the pathophysiological sequelae of CNS injury and this, combined with the non-toxic profile, lends support to agmatine being considered as a potential candidate for future clinical applications. (C) 2000 Lippincott Williams and Wilkins.",
keywords = "Agmatine, Locomotor function, Neuroprotection, Nitric oxide, NMDA",
author = "{Chen Guang Yu}, {Guang Yu} and Alexander Marcillo and Fairbanks, {C. A.} and Wilcox, {G. L.} and Yezierski, {R. P.}",
year = "2000",
month = "10",
day = "28",
language = "English (US)",
volume = "11",
pages = "3203--3207",
journal = "NeuroReport",
issn = "0959-4965",
publisher = "Lippincott Williams and Wilkins",
number = "14",

}

TY - JOUR

T1 - Agmatine improves locomotor function and reduces tissue damage following spinal cord injury

AU - Chen Guang Yu, Guang Yu

AU - Marcillo, Alexander

AU - Fairbanks, C. A.

AU - Wilcox, G. L.

AU - Yezierski, R. P.

PY - 2000/10/28

Y1 - 2000/10/28

N2 - Clinically effective drug treatments for spinal cord injury (SCI) remain unavailable. Agmatine, an NMDA receptor antagonist and inhibitor of nitric oxide synthase (NOS), is an endogenous neuromodulator found in the brain and spinal cord. Evidence is presented that agmatine significantly improves locomotor function and reduces tissue damage following traumatic SCI in rats. The results suggest the importance of future therapeutic strategies encompassing the use of single drugs with multiple targets for the treatment of acute SCI. The therapeutic targets of agmatine (NMDA receptor and NOS) have been shown to be critically linked to the pathophysiological sequelae of CNS injury and this, combined with the non-toxic profile, lends support to agmatine being considered as a potential candidate for future clinical applications. (C) 2000 Lippincott Williams and Wilkins.

AB - Clinically effective drug treatments for spinal cord injury (SCI) remain unavailable. Agmatine, an NMDA receptor antagonist and inhibitor of nitric oxide synthase (NOS), is an endogenous neuromodulator found in the brain and spinal cord. Evidence is presented that agmatine significantly improves locomotor function and reduces tissue damage following traumatic SCI in rats. The results suggest the importance of future therapeutic strategies encompassing the use of single drugs with multiple targets for the treatment of acute SCI. The therapeutic targets of agmatine (NMDA receptor and NOS) have been shown to be critically linked to the pathophysiological sequelae of CNS injury and this, combined with the non-toxic profile, lends support to agmatine being considered as a potential candidate for future clinical applications. (C) 2000 Lippincott Williams and Wilkins.

KW - Agmatine

KW - Locomotor function

KW - Neuroprotection

KW - Nitric oxide

KW - NMDA

UR - http://www.scopus.com/inward/record.url?scp=0034727461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034727461&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 3203

EP - 3207

JO - NeuroReport

JF - NeuroReport

SN - 0959-4965

IS - 14

ER -